Skip to content

Clinical trials

Observational Mouth Neoplasms trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Mouth Neoplasms Phase: Observational Clear all

114 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20013
20021
20044
20053
20062
20075
20084
20091
20103
20113
20123
20135
20143
20154
20163
20175
20184
20196
20207
20217
20224
202310
20247
20259
20265

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed48
Unknown status31
Recruiting19
Not yet recruiting7
Active, not recruiting4
Terminated3
Withdrawn2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Taiwan University Hospital18
Cairo University9
M.D. Anderson Cancer Center7
National Cancer Institute (NCI)3
Chang Gung Memorial Hospital2
Fayoum University2
The University of Hong Kong2
Travera Inc2
University of Colorado, Denver2
University of Erlangen-Nürnberg Medical School2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Mouth Neoplasms114
Squamous Cell Carcinoma of Head and Neck22
Oropharyngeal Neoplasms21
Head and Neck Neoplasms20
Laryngeal Neoplasms14
Hypopharyngeal Neoplasms10
Leukoplakia, Oral9
Lichen Planus, Oral8
Nasopharyngeal Neoplasms8
Esophageal Neoplasms7

Trials

Showing 1 to 25 of 114. Each trial links to its page on Pharma Observatory.

14 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.